Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis
Authors:
Open Access
- 1 June 2019
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 38 (6) , 608-610
Abstract
Levofloxacin is used for the treatment and prevention of multidrug-resistant tuberculosis in children, but current adult formulations are poorly palatable. A questionnaire administered to caregivers of 27 children taking a novel 100 mg dispersible taste-masked levofloxacin tablet found the new formulation to be more palatable (69%) and easier to prepare (81%) than the adult formulation. This formulation may assist children to better adhere to anti-tuberculous therapy.Keywords
This publication has 6 references indexed in Scilit:
- Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populationsInternational Journal of Pharmaceutics, 2018
- Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2017
- Global burden of drug-resistant tuberculosis in children: a mathematical modelling studyThe Lancet Infectious Diseases, 2016
- Regulatory perspectives on acceptability testing of dosage forms in childrenInternational Journal of Pharmaceutics, 2014
- Acceptability of different oral formulations in infants and preschool childrenArchives of Disease in Childhood, 2013
- Prescribing for children – taste and palatability affect adherence to antibiotics: a reviewArchives of Disease in Childhood, 2011